

Joan D Beckman

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/1391076/publications.pdf>

Version: 2024-02-01

32
papers

685
citations

840776

11
h-index

713466

21
g-index

32
all docs

32
docs citations

32
times ranked

1193
citing authors

#	ARTICLE	IF	CITATIONS
1	Heme Degradation and Vascular Injury. <i>Antioxidants and Redox Signaling</i> , 2010, 12, 233-248.	5.4	196
2	Elevated hematocrit enhances platelet accumulation following vascular injury. <i>Blood</i> , 2017, 129, 2537-2546.	1.4	90
3	Heme oxygenase-1 gene delivery by Sleeping Beauty inhibits vascular stasis in a murine model of sickle cell disease. <i>Journal of Molecular Medicine</i> , 2010, 88, 665-675.	3.9	77
4	Regulation of Heme Oxygenase-1 Protein Expression by miR-377 in Combination with miR-217. <i>Journal of Biological Chemistry</i> , 2011, 286, 3194-3202.	3.4	76
5	Red blood cells modulate structure and dynamics of venous clot formation in sickle cell disease. <i>Blood</i> , 2019, 133, 2529-2541.	1.4	51
6	Inhaled carbon monoxide reduces leukocytosis in a murine model of sickle cell disease. <i>American Journal of Physiology - Heart and Circulatory Physiology</i> , 2009, 297, H1243-H1253.	3.2	47
7	Isolation and Characterization of Ovine Luteal Pericytes and Effects of Nitric Oxide on Pericyte Expression of Angiogenic Factors. <i>Endocrine</i> , 2006, 29, 467-476.	2.2	28
8	Endothelial TLR4 Expression Mediates Vaso-Occlusive Crisis in Sickle Cell Disease. <i>Frontiers in Immunology</i> , 2020, 11, 613278.	4.8	20
9	Bortezomib for Refractory Immune-Mediated Thrombocytopenia Purpura. <i>American Journal of Therapeutics</i> , 2018, 25, e270-e272.	0.9	19
10	Novel Pathophysiological Mechanisms of Thrombosis in Myeloproliferative Neoplasms. <i>Current Hematologic Malignancy Reports</i> , 2021, 16, 304-313.	2.3	14
11	Hematocrit and incidence of venous thromboembolism. <i>Research and Practice in Thrombosis and Haemostasis</i> , 2020, 4, 422-428.	2.3	13
12	Integration of clinical parameters, genotype and epistaxis severity score to guide treatment for hereditary hemorrhagic telangiectasia associated bleeding. <i>Orphanet Journal of Rare Diseases</i> , 2020, 15, 185.	2.7	11
13	Challenges in diagnosis and management of acquired factor XIII (FXIII) inhibitors. <i>Haemophilia</i> , 2018, 24, e417-e420.	2.1	10
14	Soluble MD-2 and Heme in Sickle Cell Disease Plasma Promote Pro-Inflammatory Signaling in Endothelial Cells. <i>Frontiers in Immunology</i> , 2021, 12, 632709.	4.8	8
15	Factor XIII cotreatment with hemostatic agents in hemophilia A increases fibrin α -chain crosslinking. <i>Journal of Thrombosis and Haemostasis</i> , 2018, 16, 131-141.	3.8	6
16	Quantitative real-time polymerase chain reaction (qRT-PCR) restriction fragment length polymorphism (RFLP) method for monitoring highly conserved transgene expression during gene therapy. <i>Translational Research</i> , 2008, 152, 290-297.	5.0	4
17	High incidence of thromboembolism in patients with chronic GVHD: association with severity of GVHD and donor-recipient ABO blood group. <i>Blood Cancer Journal</i> , 2021, 11, 96.	6.2	4
18	Mechanistic rationale for factor XIII cotreatment in haemophilia. <i>Haemophilia</i> , 2019, 25, e377-e378.	2.1	3

#	ARTICLE	IF	CITATIONS
19	Ruxolitinib Reduces Endothelial Pro-Adhesive Interactions: Implications for JAK2V617+ MPN Thrombosis. <i>Blood</i> , 2020, 136, 1-1.	1.4	3
20	Gastrointestinal metastatic breast cancer unmasked by anticoagulation. <i>Current Problems in Cancer Case Reports</i> , 2020, 1, 100002.	0.1	2
21	Targeted sequencing of candidate gene regions for myelofibrosis in dogs. <i>Journal of Veterinary Internal Medicine</i> , 0, , .	1.6	2
22	Adult Langerhans histiocytosis with rare BRAF mutation complicated by massive pulmonary embolism. <i>Thrombosis Research</i> , 2020, 193, 207-210.	1.7	1
23	Transition of Human Embryonic Stem Cell-Derived Endothelial Cells to Smooth Muscle Cells in Culture as a Model for Vascular Development.. <i>Blood</i> , 2005, 106, 3683-3683.	1.4	0
24	Potential Role of Heme Oxygenase-1 in Arsenic Trioxide and Hemin-Mediated Differentiation of Human Promyelocytic Leukemia Cells. <i>Blood</i> , 2008, 112, 3981-3981.	1.4	0
25	Carbon Monoxide Decreases Leukocytosis in Murine Sickle Cell Disease Models Via Decreased Granulopoiesis.. <i>Blood</i> , 2008, 112, 1433-1433.	1.4	0
26	Heme Oxygenase-1 Gene Therapy in a Murine Model of Sickle Cell Disease.. <i>Blood</i> , 2009, 114, 1527-1527.	1.4	0
27	Carbon Monoxide Therapy Reduces Reactive Oxygen Species Production and the Short-Term Hematopoietic Stem Cell Population In Heme-Oxygenase-1 Knockout Mice. <i>Blood</i> , 2010, 116, 4767-4767.	1.4	0
28	Carbon Monoxide Therapy Modulates Hematopoietic Stem Cell Development in Heme-Oxygenase-1 Knockout Mice. <i>Blood</i> , 2011, 118, 1318-1318.	1.4	0
29	Effect of Genotype and Antifibrinolytic Therapy on the Severity of Epistaxis in Hereditary Hemorrhagic Telangiectasia. <i>Blood</i> , 2014, 124, 1515-1515.	1.4	0
30	Co-Administration of Factor XIII with Hemostatic Agents in Hemophilia Promotes Clot Stability and Composition. <i>Blood</i> , 2016, 128, 2589-2589.	1.4	0
31	Mechanism Underlying a Role for Factor XIII (FXIII) Polymorphism in Sickle Cell Disease-Associated Priapism. <i>Blood</i> , 2018, 132, 2361-2361.	1.4	0
32	Microfluidic Methods to Advance Mechanistic Understanding and Translational Research in Sickle Cell Disease. <i>Translational Research</i> , 2022, , .	5.0	0